The Efficacy of Burosumab Treatment for Hypophosphatemic Rickets: Systematic Review

Background/Objective: The approval of burosumab for the treatment of X-linked hypophosphatemia (XLH) in adults and children is a significant milestone. Nevertheless, there is a scarcity of data regarding its safety and efficacy in adolescents. The primary objective of this research is to assess the safety and effectiveness of burosumab in the treatment of hypophosphatemia rickets in adolescents.

Methods: An extensive and comprehensive search was carried out primarily utilizing the PubMed database, in accordance with the PRISMA criteria. The search parameters were confined to studies conducted in the English language that investigated the effectiveness and safety of burosumab in the treatment of hypophosphatemic rickets. Specific criteria for inclusion and exclusion were established to guarantee the quality and relevance of the research under evaluation.

Results: The study encompassed a broad spectrum of research from various geographical regions across the globe, with no particular focus on gender or age. A discernible pattern emerged, indicating a favorable efficacy of burosumab as a therapeutic intervention for hypophosphatemic rickets.

Conclusion: Burosumab seems to enhance results in both younger and older children with hypophosphatemic rickets.